Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aradigm Corp.
Aradigm receives U.S. FDA orphan drug designation of liposomal ciprofloxacin for cystic fibrosis
June 2nd, 2006
Aradigm Corp. (ARDM) announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for a proprietary liposomal formulation of ciprofloxacin for the management of cystic fibrosis. Aradigm's liposomal ciprofloxacin is an aerosolized formulation of this proven anti-infective drug that was designed to increase the drug's residence time in the lung and prolong its anti-infective properties in order to treat the related infections found in these patients. "This designation for liposomal ciprofloxacin provides us the opportunity to help accelerate our efforts behind this innovative product," said Babatunde Otulana, MD,...
Source: Medicine & Law Weekly (2006-06-02)
|
